Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn Pharma will present long-term tolerability data for AP01 (inhaled pirfenidone) at the EULAR 2026 conference in London. The poster highlights findings from the ATLAS open-label extension trial, covering up to four years of treatment in patients with progressive pulmonary fibrosis.
Key figures
- Drug Name
- AP01 (inhaled pirfenidone)
- Phase Of Trial
- open-label extension
- Treatment duration
- up to 4 years
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.